Chern Carey 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Oct 16, 2017
Insider Transaction Report
Form 4
Chern Carey
General Counsel
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$0.83/sh−41,356$34,325→ 0 totalExercise: $10.35Exp: 2026-11-14→ Common Stock (41,356 underlying) - Exercise/Conversion
Common Stock
2017-10-13+30,000→ 31,982 total - Tax Payment
Common Stock
2017-10-13$11.18/sh−11,274$126,043→ 20,708 total - Disposition to Issuer
Common Stock
2017-10-13$11.18/sh+20,708$231,515→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2017-10-13$0.83/sh−38,644$32,075→ 0 totalExercise: $10.35Exp: 2026-11-14→ Common Stock (38,644 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-10-13−30,000→ 0 total→ Common Stock (30,000 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
- [F2]Includes 773 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on May 31, 2017; 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017; and 463 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017.
- [F3]Granted under Issuer's 2015 Equity Incentive Plan.
- [F4]Under its terms the option became exercisable in installments with 25% vesting on October 24, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").
- [F5]The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- [F6]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.